Chemed (NYSE:CHE) exceeds Q3 2026 expectations

Chemed reported Q3 2026 revenue of $690.9M, exceeding estimates by 0.9%. Adjusted EPS was $6.75, a 4.9% beat. EBITDA margin was 19.4%, up from last year. Operating margin improved to 14%, but free cash flow margin dropped to 0.8%. Sales volumes declined 99.1% year-on-year.

Original reporting
Published Oct 27, 2026, 8:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Chemed (NYSE:CHE) exceeds Q3 2026 expectations — source image
Decision brief

The 30-second read

$CHEBullishHigh
01

Why it matters

The earnings beat provides a fresh catalyst for short-term trading, with potential upside for the stock.

02

Market read

Earnings surprise may prompt immediate buying pressure.

03

What to watch

Free cash flow margin fell sharply, indicating cash generation concerns.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Chemed (NYSE:CHE) posted Q3 2026 results with revenue of $690.9M versus $684.5M consensus and adjusted EPS of $6.75 versus $6.44 consensus.

Company-level read

Ticker impact

$CHEBullishHigh confidence
Context

Chemed reported Q3 2026 results beating revenue and EPS estimates, with higher adjusted EBITDA and operating margin.

Expected impact

likely upside as market prices in the revenue and EPS beat

Evidence & confidence

The beat on key metrics is fresh, primary information that can be acted on immediately.

Market effects

Healthcare services sector may see modest lift from Chemed's beat.

U.S. markets may see a small positive bias in related pharma stocks.

Limited to U.S. healthcare equities.

Counterpoint

Investors may question sustainability of margin expansion given declining sales volumes.

Key entities

  • Chemed

    U.S.-listed healthcare services provider.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.